Literature DB >> 25323529

Comparison of two immunoassays for quantification of hepatitis B surface antigen in Chinese patients with concomitant hepatitis B surface antigen and hepatitis B surface antibodies.

Weiwei Liu1, Yao Hu, Yannan Yang, Tingting Hu, Xinyu Wang.   

Abstract

Two commercial quantitative immunoassay platforms are currently available for the detection of hepatitis B surface antigen (HBsAg) within a wide range of concentrations: the Architect HBsAg assay and the Elecsys HBsAg II. However, there are limited data concerning their performance in patients who are positive for both HBsAg and anti-HBs antibodies. In the present study, 127 serum samples from Chinese patients with hepatitis B carrying both HBsAg and anti-HBs antibodies were analyzed. HBsAg levels measured in parallel using the Elecsys HBsAg II and Architect HBsAg assay were compared. There was a significant correlation between HBsAg levels measured by Elecsys HBsAg II and Architect HBsAg assay (correlation coefficient, r = 0.992, P < 0.05). Bland-Altman analysis indicated only minor discordance between the methods (mean difference between Elecsys HBsAg II and Architect HBsAg assay, -0.02 log10 IU/ml; 95 % confidence interval, -0.40-0.37 log10 IU/ml). In conclusion, the results of the quantitative Elecsys HBsAg II were highly correlated with those of the Architect HBsAg assay in patients carrying both HBsAg and anti-HBs antibodies, but differences were observed between the platforms in samples with low HBsAg levels.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25323529     DOI: 10.1007/s00705-014-2253-6

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  1 in total

1.  Analytical Performance of the Sysmex HISCL HBsAg Assay and Comparison with the Roche Elecsys HBsAg II Quant Assay in the Quantification of Hepatitis B Surface Antigen.

Authors:  Joonhong Park; Taewon Bae; Yonggon Cho; Dalsik Kim; Jaehyeon Lee
Journal:  Medicina (Kaunas)       Date:  2021-11-29       Impact factor: 2.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.